Pharmacy

Your Article Summary

See Latest Articles

Par pharmaceutical and aveva drug delivery systems receive final approval to market generic catapres tts
Par Pharmaceutical, 08/19/09

Par Pharmaceutical Companies, Inc. announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for a clonidine transdermal system. Clonidine TDS is a generic version of Boehringer Ingelheim's Catapres TTS and is the first generic seven–day patch indicated in the treatment of hypertension. Clonidine TDS is available in 0.1 mg/day, 0.2 mg/day and 0.3 mg/day strengths. Annual U.S. sales of Catapres TTS were approximately $297 million, according to IMS Health data.

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

 See all of Drug Approvals

Today in Drug/Product Alerts...keeping you current

Receive free subspecialty "5-minute updates" via email

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09

Medtronic Receives FDA Warning Letter Following Inspection of Its Mounds View, Minn. Facility
Medtronic, 11/19/09

Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
Current Medical Research and Opinion, 11/17/09

 See all of Drug/Product Alerts